| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e7b8a7632054e507d98a54cd3d11573 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_066321afcd07f96dc472ddc134cfef25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a0cabcbb35db7e4405a29fc3076c399
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a92b8c2fc6aaed000b71e20ffe56b0f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c760778a650e9a9912cb38f1f109243b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d01abe75ed43d45e28921d55d4047899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78ce9150f5c9c8bd84e88a152067909e |
| publicationDate |
2017-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2016008466-A |
| titleOfInvention |
99MTC-EDDA / HYNIC-IPSMA AS A RADIOPHARMACO FOR THE DETECTION OF OVER-EXPRESSION OF THE MEMBRANE PROSTATIC ANTIGEN. |
| abstract |
This invention relates to a new membrane-specific prostate antigen inhibitor radiopharmaceutical (iPSMA) containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing the lipophilicity of the molecule for coupling to hydrophobic PSMA sites, coupled with use HYNIC conventional as a chelating agent for the 99mTc radiometal, where ethylenediamine diacetic acid (EDDA) is used to complete the radiometal coordination sphere. The new 99mTc-EDDA / HYNIC-iPSMA radiopharmaceutical detects, with high affinity and sensitivity in vivo, the PSMA protein overexpressed in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The object of this invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) of SPECT with high sensitivity for the detection of tumors with overexpression of PSMA. |
| priorityDate |
2016-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |